Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exelon Patch for Mild Cognitive Impairment in Parkinson's Disease
NCT01519271Phase 4Completed
- Sponsor
- University of Pennsylvania
- Start
- Dec 2011
- Primary completion
- Jun 2014
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of rivastigmine in Mild Cognitive Impairment (MCI), sponsored by University of Pennsylvania. Started Dec 2011; status: completed.
02
Drugs
rivastigmine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01519271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01519271.